Abstract:
The present invention provides a method for treating cancer, which includes selecting a patient coexpressing HER2 and HER3, and administering an effective amount of a HER2 inhibitor to the patient.
Abstract:
A starting clutch control device includes a starting clutch disposed between an engine and a transmission installed to a vehicle. A torque coefficient setting section sets a torque coefficient based on a clutch speed ratio of the starting clutch and a throttle opening of the engine. A torque coefficient correction section increases the torque coefficient by a torque coefficient correction amount, increasing the torque coefficient by a progressively larger torque coefficient correction amount as the throttle opening increases, in order to increase the torque coefficient within a region of smaller clutch speed ratios (e.g., clutch speed ratios less than approximately 0.5). A hydraulic pressure control section controls hydraulic pressure supplied to the starting clutch based on the torque coefficient and the rotational speed of the engine.
Abstract:
The present invention provides a method for treating cancer, which includes selecting a patient coexpressing HER2 and HER3, and administering an effective amount of a HER2 inhibitor to the patient.
Abstract:
An ac generator for a vehicle is constituted so that the thickness in insulation layers of conductors in the slot-in portions located in the slot is smaller than the other to permit a metal portion of conductors to be much larger and to increase a density of conductors in the slots, causing heating from electrical conductors to efficiently conduct to a laminated core and a housing. On the contrary, the thickness in insulating layers of the cross-over portions is larger than the other to assure insulation capability among the coils and to prevent conductors of the cross-over portion axially exposed from the core to air from water immersion to improve an electrolytic corrosion resistibility without disposing unnecessary space among coils.
Abstract:
The present invention provides an agent for preventing or treating a trastuzumab-resistant cancer, which contains one or more medicaments selected from a cofilin inhibitor, a PAK1 inhibitor, a LIMK inhibitor, a RHO inhibitor, a ROCK1 inhibitor and a ROCK2 inhibitor.
Abstract:
The present invention provides a pharmaceutical agent containing an HER2 inhibitor and a hormonal therapeutic agent or anti-cancer agent in combination. The present invention provides a pharmaceutical agent containing (1) an HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) a hormonal therapeutic agent or an anti-cancer agent in combination.
Abstract:
Provided is a combination drug. The present invention provides a pharmaceutical agent comprising (1) a HER2 inhibitor having a pyrrolopyrimidine skeleton or pyrazolopyrimidine skeleton, and (2) not less than one pharmaceutical agent selected from an mTOR inhibitor, a PI3 kinase inhibitor and a cMet inhibitor in combination.
Abstract:
A starting clutch control device includes a starting clutch disposed between an engine and a transmission installed to a vehicle. A torque coefficient setting section sets a torque coefficient based on a clutch speed ratio of the starting clutch and a throttle opening of the engine. A torque coefficient correction section increases the torque coefficient by a torque coefficient correction amount, increasing the torque coefficient by a progressively larger torque coefficient correction amount as the throttle opening increases, in order to increase the torque coefficient within a region of smaller clutch speed ratios (e.g., clutch speed ratios less than approximately 0.5). A hydraulic pressure control section controls hydraulic pressure supplied to the starting clutch based on the torque coefficient and the rotational speed of the engine.
Abstract:
This invention relates to a compound of the following formula or a salt thereof, their production and use. ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; R.sup.3 represents hydrogen, halogen, a group bonding through a carbon atom, a group bonding through a nitrogen atom, a group bonding through an oxygen atom, or a group bonding through a sulfur atom; W represents an oxygen atom or sulfur atom; A represents a group forming a nitrogen-containing condensed ring at the 3,4- of a 1,4-thiazine ring; R.sup.1 and R.sup.2 may be combined to form a bivalent hydrocarbon group interrupted by one or more hetero atoms or an alkylene group. The above compound or a salt thereof not only has Th1 and Th2 cell function modulating activity but has splenocyte proliferation response, interleukin-5 production, and interferon-gamma production inhibitory activity and finds application as an effective therapeutic and/or prophylactic agent for allergic or autoimmune diseases or as an effective therapeutic and/or prophylactic agent for graft rejection or graft-vs-host disease.